🇺🇸 FDA
Patent

US 11066479

Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof

granted A61KA61K2039/505A61K47/6415

Quick answer

US patent 11066479 (Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jul 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
45
CPC classes
A61K, A61K2039/505, A61K47/6415, A61K47/6851, A61K47/6929